Amylyx Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMLX research report →
Range $39 – $57
Price Chart
About the company
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor.
- CEO
- Joshua Cohen
- IPO
- 2022
- Employees
- 136
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on AMLX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.35B
- P/E
- -19.38
- Fwd P/E
- 16.53
- PEG
- -0.82
- P/S
- 0.00
- P/B
- 4.34
- EV/EBITDA
- -20.52
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -41.54%
- ROIC
- -23.16%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-525,000-101.2%
- Op Income
- $-153,291,000
- Net Income
- $-144,735,000+52.0%
- EPS
- $-1.53+65.5%
- OCF Growth
- +26.4%
- FCF Growth
- +26.4%
- 52W High
- $41.14
- 52W Low
- $10.83
- 50D MA
- $29.16
- 200D MA
- $21.05
- Beta
- -0.20
- RSI (14)
- 39
- Avg Volume
- 1.58M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Amylyx delivered positive phase III LUCIDITY data for avexitide, raised substantial capital, and is now focused on NDA filing and launch prep for a potential 2027 PBH approval.· November 5, 2026
- LUCIDITY met its primary endpoint with a 55% reduction in composite level 2/3 hypoglycemic events vs. placebo (P=0.000003), and all secondary endpoints were also met.
- Management said the NDA submission for avexitide remains on track for year-end, with a potential 2027 launch if approved.
- Amylyx completed an oversubscribed equity offering and ended September with $768 million in cash and cash equivalents, up from $251 million at the end of Q2.
- Commercial planning is underway: the company is building payer, marketing, market access, patient services, and commercial operations teams, and sees endocrinologists as the primary prescribers.
- The broader pipeline continues: AMX0318 IND-enabling work is ongoing with a targeted 2027 IND filing, and AMX0114 in ALS is advancing through LUMINA cohorts.
Amylyx did not report product revenue in the call. It said LUCIDITY met its pre-specified primary endpoint with a 55% reduction in the composite rate of level 2 and level 3 hypoglycemic events versus placebo (P=0.000003), and all secondary endpoints were met; avexitide also had a favorable safety profile with no serious adverse events deemed related to treatment. Total operating expenses were $49.7 million, up 38% from the same period in 2025. R&D was $28.4 million versus $19.9 million in Q3 2025, SG&A was $21.3 million versus $16.2 million, and non-cash stock-based compensation was $10.4 million versus $7.1 million in Q3 2025. The company said its oversubscribed equity offering generated $545 million in net proceeds and lifted cash and cash equivalents to $768 million at September 30 from $251 million at the end of the second quarter. Forward-looking guidance: Amylyx remains on track to submit the avexitide NDA to the FDA by year-end and is preparing for a potential 2027 approval and launch; it is also targeting a 2027 IND filing for AMX0318.
The co-CEOs framed the quarter as a turning point for the company, centered on the positive LUCIDITY readout and the shift from development into launch readiness for avexitide. They emphasized the unmet need in PBH, the lack of approved therapies, and the belief that avexitide could become the first approved treatment. Tone-wise, management sounded upbeat and energized, repeatedly calling the year a milestone period and pointing to 2027 as another potential transformational year.
The CFO highlighted a stronger balance sheet after the equity raise, noting $545 million in net proceeds and $768 million in cash and cash equivalents at quarter-end versus $251 million at the end of Q2. He also walked through a higher cost base tied to the pivot toward commercialization and avexitide investment: total operating expenses of $49.7 million, R&D of $28.4 million, SG&A of $21.3 million, and non-cash stock compensation of $10.4 million. His comments emphasized disciplined capital allocation, investment in launch readiness, and building long-term supply with both current and new suppliers.
Analysts focused on the commercial setup for avexitide, including which physicians will prescribe it, how concentrated PBH patients are, payer utilization management, pricing, and how the new ICD-10 code may affect identification. Management said endocrinologists will be the primary prescribers, with some bariatric surgery centers also relevant, and that payer discussions are just beginning; they also argued it will be hard for payers to impose step edits when no therapies are approved for PBH. On market sizing and patient identification, management reiterated its estimate of about 160,000 U.S. PBH patients and said claims work, survey work, and field engagement have reinforced confidence in that number. The team also said the ICD-10 code is an important awareness milestone but will take time to be absorbed across the system.
The strongest bull case is that avexitide produced a clean, statistically strong phase III result in a condition with no approved therapies, and management believes physicians are already reacting positively to the data. The company also now has substantial cash to fund NDA prep, commercial buildout, and supply work, reducing near-term financing pressure.
The main risks are execution-related: Amylyx still needs to file the NDA, win FDA approval, and build a commercial operation from scratch for a new rare endocrine market. Management also acknowledged that payer conversations, pricing strategy, and ICD-10 code adoption are still early, and that the launch trajectory may build over time rather than arrive all at once.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 84.7%
- Shares Outstanding
- 128.56M
- Float Shares
- 108.88M
of shares held by institutions
223 13F filers
Buy/sell ratio 0.09. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for AMLX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Chris JacobsHouse · NY27 | Buy | Oct 12, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 19.95M | ▲ 3.22M |
| Perceptive Advisors LLC | 10.57M | ▲ 2.24M |
| Blackrock, Inc. | 10.37M | ▲ 1.54M |
| Tcg Crossover Management, LLC | 6.24M | 0 |
| Vanguard Group Inc | 5.80M | ▲ 531.16K |
| Driehaus Capital Management LLC | 5.43M | ▲ 2.39M |
| Janus Henderson Group Ltd. | 5.40M | ▲ 5.40M |
| Jupiter Topco LLC | 5.24M | ▲ 5.24M |
| Vanguard Capital Management LLC | 5.08M | ▲ 853.29K |
| Saturn V Capital Management LP | 4.47M | ▼ 152.75K |
| Ra Capital Management, L.P. | 4.28M | ▲ 4.28M |
| First Light Asset Management, LLC | 3.99M | ▲ 963.29K |
Held by 307 ETFs
Biggest fund positions in AMLX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | FRATES JAMES M | other | 20,000 |
| Nov 10, 26 | FRATES JAMES M | other | 20,000 |
| Nov 10, 26 | FRATES JAMES M | other | 20,000 |
| Nov 9, 26 | FRATES JAMES M | sell | 7,700 |
| Nov 10, 26 | FRATES JAMES M | sell | 12,800 |
| Nov 10, 26 | FRATES JAMES M | sell | 7,200 |
| Nov 9, 26 | FRATES JAMES M | sell | 12,300 |
| Nov 9, 26 | Klee Justin B. | sell | 37,483 |
| Nov 9, 26 | Klee Justin B. | sell | 62,517 |
| Nov 9, 26 | Cohen Joshua B | sell | 38,105 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AMLX coverage
Recent articles, reports, and earnings notes.
No research on AMLX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AMLX report →Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript
seekingalpha.com · Nov 15
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
businesswire.com · Nov 14
Amylyx Pharmaceuticals Q3 Earnings Call Highlights
defenseworld.net · Nov 7
Amylyx Pharmaceuticals Q3 Earnings Call Highlights
defenseworld.net · Nov 7
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
Amylyx Pharmaceuticals Q3 Earnings Call Highlights
marketbeat.com · Nov 5
Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results
businesswire.com · Nov 5
Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
businesswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.